NextCure (NASDAQ:NXTC) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of NextCure (NASDAQ:NXTC) from a hold rating to a sell rating in a report released on Saturday.

Several other equities research analysts have also weighed in on NXTC. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of NextCure in a report on Wednesday, July 15th. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.00.

NextCure Trading Down 9.8%

Shares of NASDAQ NXTC opened at $5.40 on Friday. The stock has a fifty day simple moving average of $4.35 and a two-hundred day simple moving average of $9.21. NextCure has a 1-year low of $1.55 and a 1-year high of $15.74. The firm has a market cap of $19.49 million, a price-to-earnings ratio of -0.31 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.10) by $0.23. Analysts forecast that NextCure will post -7.89 EPS for the current year.

Hedge Funds Weigh In On NextCure

Several hedge funds have recently made changes to their positions in NXTC. Marshall Wace LLP bought a new stake in shares of NextCure during the 4th quarter valued at $160,000. Millennium Management LLC bought a new position in NextCure in the 4th quarter worth about $185,000. Geode Capital Management LLC boosted its stake in NextCure by 18.6% in the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC grew its holdings in NextCure by 18.7% during the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in NextCure during the 4th quarter valued at about $988,000. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.